RT Journal Article
SR Electronic
T1 Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.14.21261931
DO 10.1101/2021.08.14.21261931
A1 Minh-Phuong Huynh-Le
A1 Roshan Karunamuni
A1 Chun Chieh Fan
A1 Lui Asona
A1 Wesley K Thompson
A1 Maria Elena Martinez
A1 Rosalind A Eeles
A1 Zsofia Kote-Jarai
A1 Kenneth R Muir
A1 Artitaya Lophatananon
A1 Johanna Schleutker
A1 Nora Pashayan
A1 Jyotsna Batra
A1 Henrik Grönberg
A1 David E Neal
A1 Børge G Nordestgaard
A1 Catherine M Tangen
A1 Robert J MacInnis
A1 Alicja Wolk
A1 Demetrius Albanes
A1 Christopher A Haiman
A1 Ruth C Travis
A1 William J Blot
A1 Janet L Stanford
A1 Lorelei A Mucci
A1 Catharine M L West
A1 Sune F Nielsen
A1 Adam S Kibel
A1 Olivier Cussenot
A1 Sonja I Berndt
A1 Stella Koutros
A1 Karina Dalsgaard Sørensen
A1 Cezary Cybulski
A1 Eli Marie Grindedal
A1 Florence Menegaux
A1 Jong Y Park
A1 Sue A Ingles
A1 Christiane Maier
A1 Robert J Hamilton
A1 Barry S Rosenstein
A1 Yong-Jie Lu
A1 Stephen Watya
A1 Ana Vega
A1 Manolis Kogevinas
A1 Fredrik Wiklund
A1 Kathryn L Penney
A1 Chad D Huff
A1 Manuel R Teixeira
A1 Luc Multigner
A1 Robin J Leach
A1 Hermann Brenner
A1 Esther M John
A1 Radka Kaneva
A1 Christopher J Logothetis
A1 Susan L Neuhausen
A1 Kim De Ruyck
A1 Piet Ost
A1 Azad Razack
A1 Lisa F Newcomb
A1 Jay H Fowke
A1 Marija Gamulin
A1 Aswin Abraham
A1 Frank Claessens
A1 Jose Esteban Castelao
A1 Paul A Townsend
A1 Dana C Crawford
A1 Gyorgy Petrovics
A1 Ron HN van Schaik
A1 Marie-Élise Parent
A1 Jennifer J Hu
A1 Wei Zheng
A1 Ian G Mills
A1 Ole A Andreassen
A1 Anders M Dale
A1 Tyler M Seibert
A1 UKGPCS collaborators
A1 APCB (Australian Prostate Cancer BioResource)
A1 NC-LA PCaP Investigators
A1 The IMPACT Study Steering Committee and Collaborators
A1 Canary PASS Investigators
A1 The Profile Study Steering Committee
A1 The PRACTICAL Consortium
YR 2021
UL http://medrxiv.org/content/early/2021/08/18/2021.08.14.21261931.abstract
AB Introduction Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.Methods In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry—the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured.Results The final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43-15.16] in ProtecT, 7.07 [6.58-7.60] in African ancestry, 10.31 [9.58-11.11] in Asian ancestry, and 11.18 [10.34-12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11-0.14). For the top 20% and top 5% of PHS290, the PPV was 0.19 (0.15-0.22) and 0.26 (0.19-0.33), respectively.Conclusion We demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations.Competing Interest StatementAll authors declare no support from any organization for the submitted work except as follows: AMD and TMS report a past research grant from the US Department of Defense. OAA reports research grants from K.G Jebsen Stiftelsen, Research Council of Norway, and South East Norway Health Authority. Authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous three years except as follows, with all of these relationships outside the present study: TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, and WebMD; he has an equity interest in CorTechs Labs and also serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. OAA reports speaker honoraria from Lundbeck. Authors declare no other relationships or activities that could appear to have influenced the submitted work except as follows: OAA has a patent application # U. S. 20150356243 pending; AMD also applied for this patent application and assigned it to UC San Diego. AMD has additional disclosures outside the present work: founder, equity holder, and advisory board member for CorTechs Labs, Inc.; founder and equity holder in HealthLytix, Inc., advisory board member of Human Longevity, Inc.; recipient of nonfinancial research support from General Electric Healthcare. OAA is a consultant for HealthLytix, Inc. Additional acknowledgments for the PRACTICAL consortium and contributing studies are described in the Supplementary Information.Funding StatementThis study was funded in part by grants from the University of California (#C21CR2060), the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), the Prostate Cancer Foundation, the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority. Funding for the PRACTICAL consortium member studies is detailed in the Supplementary Information. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies, who had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present analyses used de-identified data from the PRACTICAL consortium and have been approved by the Institutional Review Board at the University of California San Diego. All contributing studies were approved by the relevant ethics committees and performed in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProstate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium data are available upon request to the Data Access Committee (http://practical.icr.ac.uk). Questions and requests for further information may be directed to PRACTICAL{at}icr.ac.uk.